Alpha Tau Medical (NASDAQ:DRTS) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock.

Alpha Tau Medical Stock Up 23.4 %

Shares of DRTS opened at $2.53 on Wednesday. The stock has a 50 day moving average price of $2.46 and a 200 day moving average price of $2.81. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.60 and a current ratio of 11.60. The stock has a market capitalization of $176.27 million, a price-to-earnings ratio of -6.17 and a beta of 0.75. Alpha Tau Medical has a one year low of $1.75 and a one year high of $4.37.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, May 20th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Equities research analysts forecast that Alpha Tau Medical will post -0.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DRTS. Levin Capital Strategies L.P. increased its holdings in shares of Alpha Tau Medical by 2.6% in the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock valued at $999,000 after purchasing an additional 8,641 shares during the last quarter. USAdvisors Wealth Management LLC purchased a new stake in Alpha Tau Medical in the 1st quarter valued at $30,000. Telemus Capital LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter worth $89,000. Satovsky Asset Management LLC purchased a new position in shares of Alpha Tau Medical during the 4th quarter worth $176,000. Finally, Private Advisor Group LLC acquired a new position in shares of Alpha Tau Medical during the 4th quarter valued at about $176,000. 2.65% of the stock is currently owned by institutional investors and hedge funds.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.